Drug Profile
Research programme: intranasal therapeutic agents - Cognition Life Science
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator University of South Florida
- Developer Cognition Life Science; University of South Florida
- Class Antidementias; Antiparkinsonians; Cannabinoids; Non-opioid analgesics
- Mechanism of Action Cannabinoid receptor agonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Pain; Parkinson's disease; Sleep disorders
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Alzheimer's-disease in USA (Intranasal)
- 28 Feb 2020 No recent reports of development identified for research development in Pain in USA (Intranasal)
- 28 Feb 2020 No recent reports of development identified for research development in Parkinson's-disease in USA (Intranasal)